26 Nov 2012 Posted in ABPI statement By Press Office
In common with all the signatories of the document, which is available to download here, the ABPI welcomes the revision of the EU Clinical Trials Directive as an important opportunity to make Europe a more attractive location for clinical research. This statement is important as it ensures there is a clear UK position as this legislation is debated in Europe.
If you have any questions on the revision of the EU clinical trials legislation, please contact Esteban Herrero-Martinez, ABPI Head of Regulatory Affairs (email: email@example.com).
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.